Percutaneous Ethanol Ablation of an Adrenal Tumor
Daniel D. Maki1,
Ziv J. Haskal1,2,
Alexander Matthies1,
Jill Langer1,
Harvey L. Nisenbaum1,
David Vaughn3 and
Abass Alavi1
1
Department of Radiology, One Silverstein Bldg., Hospital of the University of
Pennsylvania, 3400 Spruce St., Philadelphia, PA 19104.
2
Present address: Division of Vascular and Interventional Radiology, MHB 4-100,
New York Presbyterian Hospital-Columbia, 177 Fort Washington Ave., New York,
NY 10032.
3
Department of Medicine, Hematology/Oncology Division, University of
Pennsylvania Medical Center, Philadelphia, PA 19104.

View larger version (143K):
[in a new window]
|
Fig. 1A. 78-year-old woman with weight loss and elevated serum cortisol
level. Contrast-enhanced CT obtained before treatment reveals 11-cm left
adrenal mass that contains central hypoattenuation and scattered hypervascular
components.
|
|

View larger version (146K):
[in a new window]
|
Fig. 1B. 78-year-old woman with weight loss and elevated serum cortisol
level. Contrast-enhanced CT after percutaneous ethanol ablation shows tumor to
be smaller than in A. Note central gas formation.
|
|

View larger version (143K):
[in a new window]
|
Fig. 1C. 78-year-old woman with weight loss and elevated serum cortisol
level. Axial (C) and coronal (D) FDG PET scans reveal photopenic
defect (arrows) corresponding to left adrenal mass, compatible with
near absent metabolic activity, suggesting substantial tumor cell death after
ethanol ablation.
|
|

View larger version (119K):
[in a new window]
|
Fig. 1D. 78-year-old woman with weight loss and elevated serum cortisol
level. Axial (C) and coronal (D) FDG PET scans reveal photopenic
defect (arrows) corresponding to left adrenal mass, compatible with
near absent metabolic activity, suggesting substantial tumor cell death after
ethanol ablation.
|
|

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
Copyright © 2000 by the American Roentgen Ray Society.